Third-line multiple myeloma treatment of inpatients in a German cancer center: analysis of potential cost savings due to decreased renal insufficiency
The analysis quantifies for the first time the economic saving potential of improved renal function in patients with relapsed/refractory multiple myeloma in the German healthcare system through the administration of isatuximab.
Authors
- Florian Kron (ORCID: https://orcid.org/0000-0003-4907-7490)
- Christof Scheid (ORCID: https://orcid.org/0009-0007-6539-226X)
- Julia Jeck (ORCID: https://orcid.org/0000-0002-4669-690X)
- Udo Holtick (ORCID: https://orcid.org/0000-0002-5543-0257)
- Parisa Ahmadi (ORCID: https://orcid.org/0000-0001-6892-7652)
- Florian Jakobs (ORCID: https://orcid.org/0009-0002-1548-4610)
- V. Osterkamp
Institutions
- University of Cologne (DE)
- FOM University of Applied Sciences for Economics and Management (DE)
- MSH Medical School Hamburg – University of Applied Sciences and Medical University (DE)
- Essen University Hospital (DE)
- QUIRIS Healthcare (DE)
- University Hospital Cologne (DE)
Publication Details
- Journal
- Cost Effectiveness and Resource Allocation
- Published
- 2025-03-05
- DOI
- https://doi.org/10.1186/s12962-024-00600-w
- Primary Topic
- Multiple Myeloma Research and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00